Enliven Therapeutics (ELVN) Free Cash Flow (2019 - 2026)
Enliven Therapeutics (ELVN) posted Free Cash Flow of -$19.3 million for Q1 2026, down 21.8% sequentially from -$15.8 million in Q4 2025, and up 20.11% YoY from -$16.1 million in Q1 2025.
Enliven Therapeutics (ELVN) Free Cash Flow (2019 - 2026) Analysis & Trends
Enliven Therapeutics has reported Free Cash Flow for 8 years, with the latest figure at -$19.3 million in Q1 2026.
- Quarterly Free Cash Flow rose 20.11% year-over-year to -$19.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$65.6 million (up 11.35% YoY) and the FY2025 annual result came in at -$70.5 million, up 3.79% from the prior year.
- Free Cash Flow slipped to -$19.3 million in Q1 2026 per ELVN's latest filing, from -$15.8 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$6.5 million in Q3 2022 and troughed at -$24.1 million in Q1 2025.
- A 5-year average of -$15.1 million and a median of -$15.8 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow surged 40.73% in 2022, then sank 146.25% in 2023.
- Over 5 years, Free Cash Flow stood at -$8.2 million in 2022, then sank by 51.54% to -$12.5 million in 2023, then plunged by 37.67% to -$17.2 million in 2024, then gained by 7.93% to -$15.8 million in 2025, then dropped by 21.8% to -$19.3 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$19.3 million, -$15.8 million, and -$13.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - | -18.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.63 Mn |
| Jun 30, 2026 | -18.63 Mn |
| Mar 31, 2026 | -19.29 Mn |
| Mar 31, 2026 | -19.29 Mn |
| Dec 31, 2025 | -15.84 Mn |
| Dec 31, 2025 | -15.84 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Sep 30, 2025 | -13.28 Mn |
| Jun 30, 2025 | -17.20 Mn |
| Jun 30, 2025 | -17.20 Mn |
| Mar 31, 2025 | -24.15 Mn |
| Mar 31, 2025 | -24.15 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Dec 31, 2024 | -17.20 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Sep 30, 2024 | -12.21 Mn |
| Jun 30, 2024 | -20.44 Mn |
| Jun 30, 2024 | -20.44 Mn |
| Mar 31, 2024 | -23.38 Mn |
| Mar 31, 2024 | -23.38 Mn |